This site uses cookies to bring you the best experience. Find out more
Skip to main content
↑

News

Find Out The Latest

Keep in touch with exciting developments from The Oxford Science Park and its occupiers here.

Contact us on comms@oxfordsp.com if you would like to know more about any of these stories.

You can also follow us on LinkedIn  

The Oxford Science Park appoints Jitesh Patel as Development Manager

The Oxford Science Park appoints Jitesh Patel as Development Manager

19 Jan 2022

The Oxford Science Park appoints Jitesh Patel as Development Manager. New role enables accelerated delivery of buildings for existing & new occupiers Oxford, UK, January 19 2022 – The Oxford Science Park, one of the UK’s leading parks for science and technology companies, has appointed experienced property developer Jitesh Patel to the new role of Development Manager.  He will play an important role in delivering the Park’s... Read more

The Oxford Science Park takes lease on Hayakawa Building, increasing innovation space

The Oxford Science Park takes lease on Hayakawa Building, increasing innovation space

18 Jan 2022

The Oxford Science Park takes lease on Hayakawa Building,  increasing innovation space Flexible accommodation to meet high demand for life sciences facilities Oxford, UK, January 18 2022 – The Oxford Science Park, one of the UK’s leading parks for science and technology companies, has added an extra building to its innovation hub on site by taking a lease on and management of the Hayakawa Building. Adjacent to the Magdalen Centre, the c... Read more

Exscientia & Sanofi Establish Collaboration to Develop AI-driven Pipeline of Medicines

Exscientia & Sanofi Establish Collaboration to Develop AI-driven Pipeline of Medicines

07 Jan 2022

Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines January 7, 2022 * Collaborative efforts aim to accelerate drug discovery and improve clinical success * Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection * Research will be focused on up to 15 novel small molecule... Read more

Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board

Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board

06 Jan 2022

Oxford Cancer Biomarkers appoints Joanna Smart as Chair of the Board OXFORD, UK – 6th January 2022 – Joanna Smart, an experienced Director and CEO in the life sciences sector has been appointed Non-Executive Chair of Oxford Cancer Biomarkers Ltd.  She will take a leading role in helping the company achieve its growth and funding goals at a pivotal stage of the business, building on the two recent commercial launches of cancer... Read more

First Patient Dosed in Ground-Breaking Clinical Investigation for OxSonics Therapeutics

First Patient Dosed in Ground-Breaking Clinical Investigation for OxSonics Therapeutics

05 Jan 2022

First Patient Dosed in Ground-Breaking Clinical Investigation for OxSonics Therapeutics Oxford, UK – 5th January 2022 – OxSonics® Therapeutics, a world leader in the development of ultrasound-based drug delivery systems for the treatment of cancer, today announced that the first patient had been dosed in a first-in-human clinical investigation (ISRCTN17598292) evaluating its proprietary SonoTran® Platform. SonoTran is being evaluated in a... Read more

The Daubeny Project

Imaginative design, inspiring spaces.

450,000 sq ft of
premium lab space
completing 2026

Discover More